Search Result

Results for "

renal+fibrosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (5) Amine N-methyltransferase (1) AMPK (2) Anaplastic lymphoma kinase (ALK) (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (2) Apoptosis (9) Aryl Hydrocarbon Receptor (3) Autophagy (3) Bacterial (3) Bcl-2 Family (3) Biochemical Assay Reagents (1) Bradykinin Receptor (1) Cholinesterase (ChE) (1) Collagen (5) Cytochrome P450 (4) Discoidin Domain Receptor (1) DYRK (1) Epigenetic Reader Domain (1) FAK (1) Fungal (3) Galectin (1) GLUT (1) Glutaminase (2) Glycosyltransferase (1) GSK-3 (3) Guanylate Cyclase (1) Histone Methyltransferase (4) IMPDH (1) Integrin (2) Interleukin Related (3) Isotope-Labeled Compounds (1) JAK (1) Keap1-Nrf2 (1) Microtubule/Tubulin (1) mTOR (4) Na+/K+ ATPase (1) NADPH Oxidase (1) NAMPT (1) NF-κB (4) NO Synthase (1) Organoid (1) p38 MAPK (1) Parasite (3) PDGFR (1) PI3K (1) Polo-like Kinase (PLK) (1) PPAR (2) Procollagen C Proteinase (1) PROTACs (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3) SARS-CoV (1) Sirtuin (1) STAT (1) TGF-beta/Smad (6) TGF-β Receptor (7) TNF Receptor (2) TRP Channel (1) URAT1 (1) WDR5 (1) Wnt (1) Xanthine Oxidase (1) β-catenin (1)
By Research Areas:	Cancer (19) Cardiovascular Disease (9) Endocrinology (5) Infection (8) Inflammation/Immunology (33) Metabolic Disease (10) Neurological Disease (5)

By Targets:

Akt (5)

Amine N-methyltransferase (1)

AMPK (2)

Anaplastic lymphoma kinase (ALK) (1)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (2)

Apoptosis (9)

Aryl Hydrocarbon Receptor (3)

Autophagy (3)

Bacterial (3)

Bcl-2 Family (3)

Biochemical Assay Reagents (1)

Bradykinin Receptor (1)

Cholinesterase (ChE) (1)

Collagen (5)

Cytochrome P450 (4)

Discoidin Domain Receptor (1)

DYRK (1)

Epigenetic Reader Domain (1)

FAK (1)

Fungal (3)

Galectin (1)

GLUT (1)

Glutaminase (2)

Glycosyltransferase (1)

GSK-3 (3)

Guanylate Cyclase (1)

Histone Methyltransferase (4)

IMPDH (1)

Integrin (2)

Interleukin Related (3)

Isotope-Labeled Compounds (1)

JAK (1)

Keap1-Nrf2 (1)

Microtubule/Tubulin (1)

mTOR (4)

Na+/K+ ATPase (1)

NADPH Oxidase (1)

NAMPT (1)

NF-κB (4)

NO Synthase (1)

Organoid (1)

p38 MAPK (1)

Parasite (3)

PDGFR (1)

PI3K (1)

Polo-like Kinase (PLK) (1)

PPAR (2)

Procollagen C Proteinase (1)

PROTACs (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (3)

SARS-CoV (1)

Sirtuin (1)

STAT (1)

TGF-beta/Smad (6)

TGF-β Receptor (7)

TNF Receptor (2)

TRP Channel (1)

URAT1 (1)

WDR5 (1)

Wnt (1)

Xanthine Oxidase (1)

β-catenin (1)

By Research Areas:

Cancer (19)

Cardiovascular Disease (9)

Endocrinology (5)

Infection (8)

Inflammation/Immunology (33)

Metabolic Disease (10)

Neurological Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10358

MK-2206 dihydrochloride Maximum Cited Publications 462 Publications Verification MK-2206 (2HCl)	Bcl-2 Family Apoptosis mTOR Akt GSK-3	Cardiovascular Disease Inflammation/Immunology Cancer
MK-2206 dihydrochloride (MK-2206 2HCl) is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 dihydrochloride inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 dihydrochloride induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 dihydrochloride causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 dihydrochloride can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia .

HY-101938

Sinefungin 4 Publications Verification Adenosyl-Ornithine; A-9145; Antibiotic 32232RP	Histone Methyltransferase Fungal Antibiotic Parasite	Infection Inflammation/Immunology
Sinefungin is a potent inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral multiplication . Sinefungin, a SET7/9 inhibitor, ameliorates renal fibrosis by inhibiting H3K4 methylation .

HY-108232

MK-2206 Maximum Cited Publications 462 Publications Verification	Bcl-2 Family Apoptosis mTOR Akt GSK-3	Metabolic Disease Inflammation/Immunology Cancer
MK-2206 is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia .

HY-N2995

Poricoic acid A 1 Publications Verification Poricoic acid A(F)	NF-κB Keap1-Nrf2 AMPK TGF-beta/Smad Reactive Oxygen Species (ROS)	Inflammation/Immunology Cancer
Poricoic acid A can be isolated from Poria cocos. Poricoic acid A is an orally active anti-tumor agent. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Poricoic acid A also attenuatea fibroblast activation and abnormal extracellular matrix remodeling in renal fibrosis by activating AMPK and inhibiting Smad3. Poricoic acid A significantly reduces the magnitude of rise in serum creatinine and urea levels in rat model when combined with Melatonin. Poricoic acid A ameliorates renal fibrosis and podocyte injury by attenuating oxidative stress and inflammation through regulating NF-κB and Nrf2 in IRI rodent model in combination with Melatonin .

HY-18627A

PFI-2 hydrochloride 10+ Cited Publications (R)-PFI-2 hydrochloride	Histone Methyltransferase	Infection Inflammation/Immunology Cancer
PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride is a potent and selective SET domain containing lysine methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC₅₀ value of 2.0 nM and (S)-PFI-2 shows inhibiting activity with IC₅₀ value of 1.0 μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis .

HY-12220

MM-102 4 Publications Verification HMTase Inhibitor IX	WDR5 Apoptosis NF-κB TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
MM-102 (HMTase Inhibitor IX) is a cell-permeable and tightly binding inhibitor of MLL1-WDR5 interaction (IC₅₀=2.4 nM). MM-102 can specifically inhibit the growth and induce apoptosis of leukemia cells containing MLL1 fusion protein, and reduce renal fibrosis and inflammation in mice with ischemia-reperfusion injury. In addition, MM-102 also acts as an H3K4 histone methyltransferase inhibitor to improve the development of porcine somatic cell nuclear transfer (SCNT) embryos .

HY-13102

UK-383367	Procollagen C Proteinase	Others
UK-383367 is an orally available pro-collagen C-protease inhibitor (BMP-1) with an IC₅₀ value of 44 nM. UK-383367 can reduce renal fibrosis and inflammation in chronic kidney disease (CKD) and may be used to study postoperative skin scarring .

HY-12953

R-268712	TGF-β Receptor TGF-beta/Smad Anaplastic lymphoma kinase (ALK)	Cardiovascular Disease Inflammation/Immunology Cancer
R-268712 is an orally active and selective ALK-5 inhibitor, with an IC₅₀ of 2.5 nM. R-268712 inhibits the phosphorylation of Smad3 in a dose-dependent manner with an IC₅₀ of 10.4 nM. R-268712 suppresses glomerulonephritis as well as glomerulosclerosis by inhibiting TGF-β signaling, which can be used in studies of renal fibrosis and cancer .

HY-P10899

ETTAC-2	PROTACs TGF-beta/Smad	Endocrinology
ETTAC-2 is a LRG1 PROTAC degrader, degrading LRG1 via the ubiquitin-proteasome pathway with a DC₅₀ value of 8.38 μM. ETTAC-2 penetrates damaged renal cells to reduce the extracellular secretion of LRG1. ETTAC-2 effectively inhibits the TGF-β-Smad3 signaling pathway and diminishes the secretion of fibrosis-associated extracellular matrix proteins. ETTAC-2 degrades LRG1 within fibrotic kidneys and the efficacy in inhibiting the TGF-β-Smad3 pathway both in vitro and vivo. ETTAC-2 can be used for renal fibrosis research .

HY-18627

PFI-2 10+ Cited Publications (R)-PFI-2	Histone Methyltransferase	Infection Inflammation/Immunology Cancer
PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride, a chemical probe, is a potent and selective SET domain containing lysine methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC₅₀ value of 2.0 nM and (S)-PFI-2 shows inhibiting activity with IC₅₀ value of 1.0 μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis .

HY-N2181

Acetylshikonin 3 Publications Verification	Cytochrome P450 Apoptosis Bacterial Autophagy	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Acetylshikonin is an oral active anti-cancer, anti-inflammatory, antioxidant, anti-fertility, antibacterial, and neuroprotective agent. Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC₅₀=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty liver disease (NAFLD) .

HY-110217

BMS-566419	IMPDH	Inflammation/Immunology
BMS-566419 is an orally active IMPDH inhibitor with an IC₅₀ of 91 nM against human IMPDH I and 68 nM against human IMPDH II. BMS-566419 exerts anti-heart transplant rejection and anti-renal fibrosis effects, and inhibits the expression of MCP-1, TGF-β1 as well as antibody production. BMS-566419 can be used in research on renal fibrosis and organ transplantation .

HY-P99512

Zampilimab UCB-7858	Glutaminase	Endocrinology
Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab inhibits TG2 crosslinking transamidation activity with an IC₅₀ of 0.25 nM and a K_d of <50 pM. Zampilimab improves renal fibrosis .

HY-W014075

1-Hydroxypyrene	Aryl Hydrocarbon Receptor Cytochrome P450 Collagen	Inflammation/Immunology
1-Hydroxypyrene, a biomarker of exposure to polycyclic aromatic hydrocarbons (PAHs), is analyzed in urine samples. 1-Hydroxypyrene is the major biomarker of exposure to pyrenes. 1-Hydroxypyrene is the orally active agonist for aryl hydrocarbon receptor (AhR) and can lead to renal fibrosis .

HY-P11178

Corisin	Apoptosis SARS-CoV	Infection Metabolic Disease Inflammation/Immunology
Corisin is a pro-apoptotic small peptide produced by Staphylococcus species. Corisin binds to serum albumin to target organs such as the lungs and kidneys, induces cellular senescence, apoptosis and epithelial-mesenchymal transition, and accelerates the progression of organ fibrosis including pulmonary fibrosis and diabetic renal fibrosis. Corisin levels are closely associated with coronavirus disease 2019 (COVID-19), diabetic chronic kidney disease (CKD), non-diabetic CKD, and idiopathic pulmonary fibrosis (IPF) .

HY-18758

IN-1130 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC₅₀ of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC₅₀=36 nM) and p38α mitogen-activated protein kinase (IC₅₀=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-112597A

Mavodelpar REN001; HPP593	PPAR	Inflammation/Immunology
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD) . Mavodelpar is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N3225

Myricanol	NAMPT Sirtuin Microtubule/Tubulin Apoptosis Autophagy PDGFR NF-κB AMPK	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Myricanol is a diarylheptanoid and a Nampt activator. Myricanol exerts anti-inflammatory effects and alleviates glucocorticoid-induced muscle atrophy by increasing Sirtuin 1 (SIRT1) and PRDX5 activities while regulating inflammatory factors. Myricanol exhibits growth inhibition and induces apoptosis in human lung adenocarcinoma A549 cells. Myricanol promotes autophagy-mediated clearance of microtubule-associated protein tau to exert neuroprotective effects. Myricanol protects cardiovascular function by inhibiting PDGFRβ and NF-κB signaling pathways. Myricanol activates mitochondrial transcription factor A (TFAM) expression to exert anti-renal fibrosis effects. Myricanol improves insulin resistance through AMPK activation .

HY-128439

BT173	DYRK	Cancer
BT173 is a potent homeodomain interacting protein kinase 2 (HIPK2) inhibitor. BT173 binds to HIPK2 and does not inhibit HIPK2 kinase activity but rather, interfered allosterically with the ability of HIPK2 to associate with Smad3. BT173 attenuates renal fibrosis through suppression of the TGF-β1/Smad3 pathway. BT173 can be studied in research for kidney diseases such as renal fibrosis .

HY-W014075S

1-Hydroxypyrene-d9	Isotope-Labeled Compounds Aryl Hydrocarbon Receptor Cytochrome P450 Collagen	Inflammation/Immunology
1-Hydroxypyrene-d₉ is the deuterium labeled 1-Hydroxypyrene (HY-W014075). 1-Hydroxypyrene, a biomarker of exposure to polycyclic aromatic hydrocarbons (PAHs), is analyzed in urine samples. 1-Hydroxypyrene is the major biomarker of exposure to pyrenes. 1-Hydroxypyrene is the orally active agonist for aryl hydrocarbon receptor (AhR) and can lead to renal fibrosis .

HY-P990107

Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8)	TGF-β Receptor	Cancer
Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) is an TGF-β IgG antibody inhibitor. Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) reduces renal fibrosis in unilateral ureteral obstruction (UUO) mice models. Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) shows potent anti-tumor effect in various tumor models, such as pancreatic cancer .

HY-N0885

Telocinobufagin 1 Publications Verification Telobufotoxin; Telocinobufogenin	JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na ⁺/K ⁺-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models .

HY-N10423

Cubebin (-)-Cubebin	Cholinesterase (ChE) Bacterial Fungal Parasite p38 MAPK	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Cubebin ((-)-Cubebin), a dibenzyl butyrolactone lignan, is an orally active AChE inhibitor. Cubebin binds to active sites of NF-κB, TNF-α, and TGF-β1 via hydrogen and hydrophobic interactions, obstructing critical residues to inhibit pro-inflammatory or renal fibrosis-related activity. Cubebin enhances p38 MAPK phosphorylation to increase tyrosinase gene expression, stimulating melanogenesis via elevated tyrosinase activity, expression, and mRNA levels. Cubebin reduces oxidative stress via enhanced endogenous antioxidant enzyme activity and inhibited lipid peroxidation, regulates lipid metabolism, improves glycemic control, and exerts renoprotective effects via reduced renal dysfunction markers and improved renal architecture. Cubebin shows antimicrobial activity. Cubebin exerts larvicidal activity against Angiostrongylus cantonensis larvae, with no cytotoxicity toward monkey or human cell lines or Caenorhabditis elegans. Cubebin can be used for the research of diabetic nephropathy, melanoma, colon adenocarcinoma, neuroangiostrongyliasis, Alzheimer’s disease (AD) and depression .

HY-P99121

Anti-Mouse/Human CD11b Antibody (M1/70)	Integrin	Inflammation/Immunology Cancer
Anti-Mouse/Human CD11b Antibody (M1/70) is an anti-mouse CD11b IgG2b monoclonal antibody. Anti-Mouse/Human CD11b Antibody (M1/70) can significantly inhibit the adhesion between dendritic cells (DCs) and platelets. Anti-Mouse/Human CD11b Antibody (M1/70) can kill ovarian cancer cells and inhibit their migration. Anti-Mouse/Human CD11b Antibody (M1/70) can alleviate renal fibrosis and inflammation. Anti-Mouse/Human CD11b Antibody (M1/70) can be used for researches on inflammation conditions and cancer such as ischemia-reperfusion injury (IRI), thrombotic inflammatory conditions and ovarian cancer .

HY-P3209

Des-Arg9-[Leu8]-Bradykinin acetate	Bradykinin Receptor	Inflammation/Immunology
Des-Arg9-[Leu8]-Bradykinin acetate is potent bradykinin receptor 1 (B1R) antagonist. Des-Arg9-[Leu8]-Bradykinin acetate can be used for renal fibrosis research .

HY-130579

Vinyl-L-NIO hydrochloride L-VNIO hydrochloride	NO Synthase NADPH Oxidase	Cardiovascular Disease Neurological Disease
Vinyl-L-NIO (L-VNIO) hydrochloride is a neuronal nitric oxide synthase (NOS) inhibitor with a rat K_i of 0.10 μM. Vinyl-L-NIO hydrochloride inhibits NADPH oxidase activity, attenuates renal fibrosis, inflammation, oxidative stress indices, and albuminuria. Vinyl-L-NIO hydrochloride can be used for the research of parkinson's disease, migraine headache, and hypertension .

HY-10357

MK-2206 free base	Akt mTOR Apoptosis GSK-3 Bcl-2 Family	Metabolic Disease Inflammation/Immunology Cancer
MK-2206 free base is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 free base inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 free base induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 free base causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 free base can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia .

HY-P6441

KP-6	β-catenin Wnt	Inflammation/Immunology
KP-6, a polypeptide, is a Wnt/β-catenin signal inhibitor. KP-6 inhibits TGF-β and blocks rush fibrosis signal path crucial in vivo. KP-6 suppresses Renal tissues damage and renal fibrosis, and reverse the course of disease of chronic kidney disease (CKD) .

HY-163121

PST3.1a	Glycosyltransferase TGF-β Receptor FAK Galectin Collagen	Endocrinology Cancer
PST3.1a is an orally active and brain-penetrant N-acetylglucosamine glycosyltransferase (MGAT5) inhibitor with a human IC₅₀ of 2 µM. PST3.1a inhibits TGFβR and FAK signaling pathway activity. PST3.1a alters β1,6-GlcNAc N-glycans and microtubule/microfilament integrity, increases OLIG2 expression, and inhibits proliferation, migration, invasiveness, and clonogenic capacities of glioblastoma initiating cells. PST3.1a reduces invasive and proliferative capacity of glioblastoma initiating cells in orthotopic graft models, increases overall survival of orthotopic graft model mice. PST3.1a blunts MGAT5 overexpression, decreases renal fibrosis via collagen 1, collagen 4, and galectin 3 downregulation in a rat chronic kidney disease model. PST3.1a can be used for the research of glioblastoma multiforme and chronic kidney disease .

HY-30099

O,O,S-Trimethyl ester phosphorothioic acid	Biochemical Assay Reagents
O,O,S-Trimethyl ester phosphorothioic acid is a chemical substance with biological activity for studying renal fibrosis. O,O,S-Trimethyl ester phosphorothioic acid can be used as an experimental model for studying renal fibrosis.

HY-123409

Nicousamide	TGF-β Receptor	Metabolic Disease
Nicousamide is a potent inhibitor of TGF-β RII phosphorylation. Nicousamide can be used to study renal fibrosis in animal models of diabetic nephropathy .

HY-N10438

Ganodermaones B	Integrin	Inflammation/Immunology
Ganodermaones B (Compound 2) is a renal fibrosis inhibitor. Ganodermaones B inhibits TGF-β1-induced collagen I and fibronectin expression .

HY-N3674

Dalbergioidin	TGF-beta/Smad	Inflammation/Immunology
Dalbergioidin, a well-known anthocyanin, ameliorates doxorubicin-induced renal fibrosis by suppressing the TGF-β signal pathway. Dalbergioidin exhibits tyrosinase inhibitory activity with an IC₅₀ of 20 mM .

HY-122445

Resorcinolnaphthalein 2 Publications Verification	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease Inflammation/Immunology
Resorcinolnaphthalein is a specific angiotensin-converting enzyme 2 (ACE2) enhancer and activates ACE2 activity with an EC₅₀ value of 19.5 μM. Resorcinolnaphthalein can be used for the investigation of hypertension and renal fibrosis .

HY-142698

SGC agonist 2	Guanylate Cyclase	Cardiovascular Disease
SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031) .

HY-174348

BRD4-IN-10	Epigenetic Reader Domain	Inflammation/Immunology
BRD4-IN-10 (Compound 31) is a selective BRD4 inhibitor with an IC₅₀ of 13.5 nM. BRD4-IN-10 can exert anti-inflammatory and anti-fibrotic effects. BRD4-IN-10 also has good metabolic stability, pharmacokinetic properties and safety. BRD4-IN-10 can be used in the research of renal fibrosis diseases .

HY-W014075R

1-Hydroxypyrene (Standard)	Reference Standards Aryl Hydrocarbon Receptor Cytochrome P450 Collagen	Inflammation/Immunology
1-Hydroxypyrene (Standard) is the analytical standard of 1-Hydroxypyrene (HY-W014075). This product is intended for research and analytical applications. 1-Hydroxypyrene, a biomarker of exposure to polycyclic aromatic hydrocarbons (PAHs), is analyzed in urine samples. 1-Hydroxypyrene is the major biomarker of exposure to pyrenes. 1-Hydroxypyrene is the orally active agonist for aryl hydrocarbon receptor (AhR) and can lead to renal fibrosis.

HY-172600

TRPC6 antagonist-1	TRP Channel	Inflammation/Immunology
TRPC6 antagonist-1 (X26) is a TRPC6 antagonist with IC₅₀ values of 0.97 μM, 3.93 μM, 5.77 μM and 4.37 μM for TRPC6, TRPC3, TRPC5 and TRPC7, respectively. TRPC6 antagonist-1 inhibits TGF-β1-induced myofibroblast differentiation, and attenuates renal fibrosis .

HY-18758R

IN-1130 (Standard)	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 (Standard) is the analytical standard of IN-1130. This product is intended for research and analytical applications. IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC50 of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC50=36 nM) and p38α mitogen-activated protein kinase (IC50=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-P11609

TGFβ1-IN-4	TGF-beta/Smad	Metabolic Disease
TGFβ1-IN-4 is a TGF-β1 inhibitor. TGFβ1-IN-4 inhibits myofibroblast activation and epithelial-mesenchymal transition in vitro. TGFβ1-IN-4 alleviates renal fibrosis in a mouse model of renal fibrosis. TGFβ1-IN-4 can be used for research on fibrotic diseases such as renal fibrosis .

HY-182021

NNMT-IN-8	Amine N-methyltransferase	Endocrinology
NNMT-IN-8 is a non-SAM-mimicking bisubstrate inhibitor and a selective methyltransferase NNMT inhibitor, with IC₅₀ values of 0.0084 μM and 0.0085 μM against human NNMT, and an IC₅₀ of 0.0072 μM against mouse NNMT. NNMT-IN-8 exhibits prominent renal distribution characteristics and moderate bioavailability in rodents. NNMT-IN-8 dose-dependently inhibits renal NNMT in renal fibrosis models, thereby exerting antifibrotic effects. NNMT-IN-8 can be used to investigate the mechanisms of renal fibrosis .

HY-N17639

Regiafuran C	TGF-beta/Smad TGF-β Receptor	Others
Regiafuran C is a compound with both TGF-βRI inhibitory and anti-fibrotic activities. Regiafuran C effectively inhibits renal fibrosis by binding to TGF-βRI and interfering with the TGF-β/Smad and Wnt/β-catenin signaling pathways. Regiafuran C also exhibits free radical scavenging activity, but shows no anti-inflammatory activity in PGE2 competitive enzyme immunoassays. The ability of Regiafuran C to specifically block the Smad3-TGF-βRII interaction and inhibit fibrotic processes allows its use in renal fibrosis research .

HY-181652

PPARδ agonist 13	PPAR	Endocrinology
PPARδ agonist 13 is a potent, selective and orally active PPARδ agonist with an EC₅₀ values of 0.50 nM. PPARδ agonist 13 binds to the PPARδ ligand-binding pocket and upregulates PPARδ target gene expression. PPARδ agonist 13 inhibits renal fibroblast activation, restores fatty acid oxidation, and attenuates TGF-β1-induced renal fibroblast activation. PPARδ agonist 13 exhibits anti-renal fibrosis effects in a mouse model of unilateral ureteral obstruction. PPARδ agonist 13 can be used for the research of renal fibrosis .

HY-P992066

Anti-Mouse DDR2 Antibody (DAB0065)	Discoidin Domain Receptor	Inflammation/Immunology
Anti-Mouse DDR2 Antibody (DAB0065) is a mAb that specifically targets mouse discoidin domain receptor DDR2 without cross-reacting with DDR1. Anti-Mouse DDR2 Antibody (DAB0065) binds to the extracellular domain of native mouse DDR2, induces endocytosis and lysosomal degradation of DDR2, and this process is independent of collagen binding. Anti-Mouse DDR2 Antibody (DAB0065) exhibits significant therapeutic effects in both the unilateral ureteral obstruction (UUO) mouse model of renal fibrosis and the bleomycin (HY-108345)-induced mouse model of pulmonary fibrosis, effectively downregulating the mRNA expression of type I collagen Col1a1 and fibronectin Fn1. Anti-Mouse DDR2 Antibody (DAB0065) can be humanized and has the potential to be developed as a targeted agent for diseases such as idiopathic pulmonary fibrosis and renal fibrosis .

HY-101938R

Sinefungin (Standard) Adenosyl-Ornithine (Standard); A-9145 (Standard); Antibiotic 32232RP (Standard)	Reference Standards Histone Methyltransferase Fungal Antibiotic Parasite	Infection Inflammation/Immunology
Sinefungin (Standard) is the analytical standard of Sinefungin (HY-101938). This product is intended for research and analytical applications. Sinefungin is a potent inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral multiplication . Sinefungin, a SET7/9 inhibitor, ameliorates renal fibrosis by inhibiting H3K4 methylation .

HY-P11623

4L2-P13D	Interleukin Related Collagen	Inflammation/Immunology
4L2-P13D is an IL-11 antagonist with an IC₅₀ of 2.8 μM. 4L2-P13D has a K_D of 11 nM for hIL-11. 4L2-P13D exhibits antifibrotic and renoprotective activities. 4L2-P13D can be used in the research of renal fibrosis .

HY-180322

TG2-IN-3h	Glutaminase	Cardiovascular Disease Metabolic Disease
TG2-IN-3h (Compound 3h) is a transglutaminase (TG2) inhibitor (hTG2: IC₅₀ = 6nM). TG2-IN-3h inhibits endothelial cell migration and angiogenesis. TG2-IN-3h alleviates renal fibrosis in a mouse model of hypertensive nephropathy. TG2-IN-3h can be used in research on metabolic diseases such as hypertensive nephropathy and cardiovascular and cerebrovascular diseases such as pathological angiogenesis .

HY-180271

Xanthine oxidase-IN-21	Xanthine Oxidase NF-κB TNF Receptor Interleukin Related URAT1 GLUT	Metabolic Disease
Xanthine oxidase-IN-21, a Genipin (HY-17389) derivative, is an orally active mixed competitive xanthine oxidase (XOD) inhibitor with an IC₅₀ of 0.68 μM. Xanthine oxidase-IN-21 reduces renal fibrosis by decreasing α-SMA expression and suppresses pro-inflammatory cytokines IL-1β, IL-6, and TNF-α through NF-κB pathway regulation. Xanthine oxidase-IN-21 also inhibits URAT1 and GLUT9 expression, promoting uric acid excretion and lowering serum uric acid levels. Xanthine oxidase-IN-21 shows significantly hepatorenal protection activity. Xanthine oxidase-IN-21 can be used for the research of hyperuricemia .

HY-10358R

MK-2206 dihydrochloride (Standard) MK-2206 (2HCl) (Standard)	Organoid Reference Standards Akt Autophagy Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
MK-2206 dihydrochloride (MK-2206 2HCl) (Standard) is the analytical standard of MK-2206 dihydrochloride (HY-10358). This product is intended for research and analytical applications. MK-2206 dihydrochloride is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 dihydrochloride inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 dihydrochloride induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 dihydrochloride causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 dihydrochloride can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia .

Cat. No.	Product Name	Target	Research Area